Barry Simon, M.D. – Chairman of the Board
Barry Simon is President and COO of Nantkwest since its inception. Dr. Simon previously held various senior level executive and advisory positions at Roche Labs, F. Hoffmann-La Roche (VTX: ROG), Connetics Corp. (NASDAQ: CNCT), Immunomedics (NASDAQ: IMMU), Immusol, NorthSound Capital, LLC, and HealthPro BioVentures. He has broad experience with product and portfolio divestitures and acquisitions, strategic licensing and joint ventures in addition to commercial product launches, IND and BLA regulatory filings, human-enabling programs, manufacturing, quality control and life cycle management. Dr. Simon attended corporate training programs by the London School of Business and the Amos Tuck School of Business at Dartmouth College. He trained clinically in infectious diseases, anesthesiology and internal medicine and received his M.D. from the SUNY Downstate, Health Sciences Center in New York.
Peter Kiener, D.Phil.
Peter Kiener has deep experience in both biologics and immunotherapy, and is the former Chief Scientific Officer at Sucampo. Prior to joining Sucampo, he served as CSO of Ambrx Inc., a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates. Prior to Ambrx, Dr. Kiener was President and Co-founder of Zyngenia Inc., an early-stage biopharmaceutical company. He also held leadership roles at MedImmune LLC, the global biologics arm of AstraZeneca, including Executive Vice President and Global Head of Biologics Research and Development, Senior Vice President and Head of Global Research, and Vice President of Research. He also worked on biologics for Bristol-Myers Squibb prior to his work at MedImmune. Dr. Kiener has served on the scientific advisory boards of KAI Pharmaceuticals Inc., Genocea Biosciences Inc., NKT Therapeutics Inc. and VLST Corporation and as a member of the Board of Directors of Receptor BioLogix Inc., Synovex Corporation and Virdante Pharmaceuticals Inc. He has published more than 120 papers in peer-reviewed journals and is an inventor on more than 40 patents and patent applications. Dr. Kiener earned a bachelor’s degree in chemistry from the University of Lancaster and a doctorate of philosophy in biochemistry from the University of Oxford.
Steven McKnight, Ph.D.
Steven McKnight leads an active research laboratory at UT Southwestern Medical Center. Prior to his work there, Dr. McKnight was co-founder and Director of Biology at Tularik, Inc. Previously he was a Howard Hughes Medical Institute investigator at the Carnegie Institution of Washington. He is a member of the National Academy of Sciences, the Institute of Medicine, and the American Academy of Arts and Sciences. Dr. McKnight served on the Board of Directors for Tularik from its inception through its acquisition by Amgen in 2004. He also co-founded and served as a board member for Cumbre, Inc., and Peloton Therapeutics. Dr. McKnight holds a B.S. in biology from The University of Texas at Austin and a Ph.D. in biology from the University of Virginia.
Fred Driscoll has more than 20 years of experience in financial management of life sciences companies, most recently as the Chief Financial Officer at Flexion Therapeutics, Inc., where he spearheaded an initial public offering in 2014. Prior to joining Flexion, he served as Chief Financial Officer at Novavax, Inc. from 2009 to 2013. From 2008 to 2009, Mr. Driscoll served as Chief Executive Officer of Genelabs Technologies, Inc., a publicly traded biopharmaceutical and diagnostics company later acquired by GlaxoSmithKline. Prior to serving as Chief Executive Officer of Genelabs he was the Chief Financial Officer from 2007 to 2008. From 2000 to 2006, Mr. Driscoll served as Chief Executive Officer at OXiGENE, Inc., where he also served as Chairman of the Board and Audit Committee Chair. He was also a member of the Audit Committee for Cynapsus Therapeutics, Inc., which was sold to Sunovion Pharmaceuticals in 2016. Mr. Driscoll earned a B.S. in accounting and finance from Bentley University. He is a member of the board of directors of Cellectar Biosciences, Inc., MEI Pharma, Inc. and NantKwest, Inc.
Frank Morich, M.D., Ph.D.
Dr. Frank Morich is a biopharmaceutical professional with more than 35 years of industry experience. He currently serves on the board of directors for MorphoSys (since May 2015) and served as a board member for Innate Pharma between 2004-2010, both clinical-stage biotechnology companies specializing in antibody development. Prior to focusing on board work, from 2011 to 2014, Dr. Morich served as Chief Commercial Officer at Takeda Pharmaceuticals, a global pharmaceutical company, and, from 2010 to 2011, he served as Executive Vice President, International Operations at Takeda. From 2008 to 2010, Dr. Morich served as Chief Executive Officer of NOXXON Pharma AG, a clinical-stage drug development company, and, from 2005 to 2007, he served as Chief Executive Officer and member of the board of directors of Innogenetics N.V., an international in vitro diagnostics company. Prior to that, Dr. Morich held several positions at Bayer, a global pharmaceutical and life sciences company, including member of the Board of Management of Bayer AG, Head of Global Product Development and Head of Research and Development. Dr. Morich holds an M.D. and Ph.D. from the University of Marburg where he specialized in immunology with a focus on monoclonal antibodies. He served as a military physician before moving to industry.
Christopher A. Marlett
Christopher Marlett joined our board of directors in June 2015. Mr. Marlett is, and has been since 1997, the Chief Executive Officer and a co-founder of MDB Capital Group. He has also served on the board of directors of the Maven, Inc., a developer of a network of professionally-managed online media channels since April 2008. Mr. Marlett has over twenty-seven years of investment banking experience, including all phases of corporate finance, such as the completion of initial public offerings, secondary offerings, PIPEs and strategic consulting. He holds a B.S. in Business Administration from the University of Southern California.
Anthony DiGiandomenico joined our board of directors in June 2015. He has served on the boards of directors of ENDRA Life Sciences Inc., a developer of enhanced ultrasound technology, since July 2013, and Provention Bio, Inc., a biopharmaceutical company, since April 2017. Since he co-founded MDB Capital Group in 1997, Mr. DiGiandomenico has been enabling investment into early-stage disruptive technologies. He has worked alongside a wide range of companies in the biotechnology, medical devices, high technology, and renewable energy spaces. Mr. DiGiandomenico holds an MBA from the Haas School of Business at the University of California, Berkeley and a B.S. in Finance from the University of Colorado.
Cameron Gray, Ph.D.
Cameron Gray has been a member of our board of directors since January 2015 and served as our Chief Executive Officer from June 2015 to August 2016. He is also a Managing Director at MDB Capital Group. Dr. Gray has been with MDB since September 2013. Prior to joining MDB Capital Group, Dr. Gray served as Chief Executive Officer and a member of the board of directors of Endeavor IP, Inc., an intellectual property services and patent licensing company, from May 2013 through January 2014. Prior to that, he was Senior Vice President at ICAP Patent Brokerage, LLC, where he managed its life sciences and Asia Pacific businesses from January 2009 through January 2012. Dr. Gray has a J.D. from George Washington University School of Law, a Ph.D. in biophysics from the University of Virginia, and a B.A. in physics from Princeton University.